<DOC>
	<DOCNO>NCT02835170</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled parallel group study efficacy , safety intramuscular injection autologous immunoglobulin patient moderate-to-severe atopic dermatitis .</brief_summary>
	<brief_title>Development Personalized Immune-modulating Therapy Patients With Atopic Dermatitis</brief_title>
	<detailed_description>Children adult patient moderate-to-severe atopic dermatitis ( age ≥ 13 year ) whose clinical condition effectively control current standard medical therapy ( topical moisturizers , topical corticosteroid , topical calcineurin inhibitor , oral antihistamine ) 2 month include . This randomized , double-blind , placebo-controlled parallel group study efficacy , safety intramuscular injection autologous immunoglobulin patient moderate-to-severe atopic dermatitis . After provide informed consent , patient assess study eligibility baseline visit . Patients undergo screen within 28 day prior randomization `` wash period '' , screen period , treatment medication ( include systemic corticosteroid systemic immunomodulating agent ) atopic dermatitis wash-out least 28 day prior baseline ( exclude moisturizers ) . Topical corticosteroid topical calcineurin inhibitor require stop least 7 consecutive day baseline . At screening , plasma separate patient ' venous blood ( 400ml ) aseptically autologous immunoglobulin fraction purify plasma chromatography use Protein A screening period . Patients randomize 1:1 ratio receive weekly treatment autologous immunoglobulin placebo ( normal saline ) 2 month administrate intramuscular injection , week 7 week ( total 8 injection ) . The investigator evaluate clinical efficacy safety intramuscular injection autologous immunoglobulin patient moderate-to-severe atopic dermatitis measuring change standardize clinical severity score system atopic dermatitis ( SCORAD ) value , Eczema Area Severity index ( EASI ) , Investigator 's Global Assessment ( IGA ) quality life together laboratory parameter blood sample treatment .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Suitability autologous blood donation criterion 2 . Current standard medical therapy 2 month moderatetosevere atopic dermatitis 3 . ≥10 % lesion body surface area ( BSA ) atopic dermatitis involvement area 1 . Patients age 13 year . 2 . Patients unable agree ( emergency patient , patient mental disability , patient limited capacity consent due stroke delirium cause diabetes ) . 3 . Patients severe disease whose expected survival duration le 3 month . 4 . Pregnancy plan pregnancy within 1 year 5 . Skin condition appropriate blood sample transfusion 6 . The standardized clinical severity score system atopic dermatitis ( SCORAD ) value &lt; 25 ( Mild atopic dermatitis )</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Immunoglobulin G</keyword>
	<keyword>Treatment</keyword>
</DOC>